Skip to main content

Advertisement

SpringerLink
Log in

Phosphodiesterase-5 inhibitors: Clinical market and basic science comparative studies

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

The purpose of this review is to examine the biologic, pharmacologic, and clinical differences between the three currently approved phosphodiesterase-5 inhibitors to help the clinician make an educated choice about which medication may be best for any individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Feldman HA, Johannes CB, Derby CA, et al.: Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med 2000, 30:328–338.

    Article  PubMed  CAS  Google Scholar 

  2. Seidman SN: Exploring the relationship between depression and erectile dysfunction in aging men. J Clin Psychiatry 2002, 63(suppl 5):5–12.

    PubMed  Google Scholar 

  3. Feldman HA, Goldstein I, Hatzichristou DG, et al.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151:54–61.

    PubMed  CAS  Google Scholar 

  4. Corbin JD, Francis SH, Webb DJ: Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 2002, 60(suppl 2):4–11.

    Article  PubMed  Google Scholar 

  5. Soderling SH, Beavo JA: Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 2000, 12:174–179.

    Article  PubMed  CAS  Google Scholar 

  6. Sung BJ, Hwang KY, Jeon YH, et al.: Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 2003, 425:98–102.

    Article  PubMed  CAS  Google Scholar 

  7. Corbin JD, Turko IV, Beasley A, et al.: Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 2000, 267:2760–2767.

    Article  PubMed  CAS  Google Scholar 

  8. Fawcett L, Baxendale R, Stacey P, et al.: Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A 2000, 97:3702–3707.

    Article  PubMed  CAS  Google Scholar 

  9. Hetman JM, Robas N, Baxendale R, et al.: Cloning and characterization of two splice variants of human phosphodiesterase 11A. Proc Natl Acad Sci U S A 2000, 97:12891–12895.

    Article  PubMed  CAS  Google Scholar 

  10. Blount MA, Beasley A, Zoraghi R, et al.: Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 2004, 66:144–152. Critical study.

    Article  PubMed  CAS  Google Scholar 

  11. Nichols DJ, Muirhead GJ, Harness JA: Pharmacokinetics of sildenafil after single oral doses in healthly male subjects: absolute bioavailability, food effects, and dose proportionality. J Clin Pharmacol 2002 53(suppl1):5S-12S.

    CAS  Google Scholar 

  12. Bischoff E: Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Import Res 2004, 16(suppl 1):S34-S37.

    Article  CAS  Google Scholar 

  13. Padma-Nathan H, Stecher VJ, Sweeney M, et al.: Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003, 62:400–403.

    Article  PubMed  CAS  Google Scholar 

  14. Lilly ICOS: Cialis Package Insert. Cialis® (tadalafil) prescribing information. Indianapolis: Eli Lilly and Company; 2003.

    Google Scholar 

  15. Padma-Nathan H: Abstract 41. J Androl 2003, 48(suppl).

  16. Moncada I, Jara J, Subira D, et al.: Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol 2004, 46:357–360.

    Article  PubMed  CAS  Google Scholar 

  17. Porst H, Padma-Nathan H, Giuliano F, et al.: Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized, controlled trial. Urology 2003, 62:121–125.

    Article  PubMed  Google Scholar 

  18. Wechsler H, Lee JE, Kuo M, et al.: Trends in college binge drinking during a period of increased prevention efforts. Findings from four Harvard School of Public Health College Alcohol Study surveys: 1993–2001. J Am Coll Health 2002, 50:203–217.

    Article  PubMed  Google Scholar 

  19. Muirhead GJ, Wulff MB, Fielding A, et al.: Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000, 50:99–107.

    Article  PubMed  CAS  Google Scholar 

  20. Boshier A, Wilton LV, Shakir SA: Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU Int 2004, 93:796–801.

    Article  PubMed  CAS  Google Scholar 

  21. Stief C, Porst H, Saenz De Tejada I, et al.: Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004, 58:230–239.

    Article  PubMed  CAS  Google Scholar 

  22. Montorsi F, Verheyden B, Meuleman E, et al.: Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004, 45:339–344.

    Article  PubMed  CAS  Google Scholar 

  23. Seftel AD: Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol 2004, 27(suppl 1):I14-I19.

    Article  PubMed  Google Scholar 

  24. Hellstrom WJ, Overstreet JW, Yu A, et al.: Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003, 170:887–891.

    Article  PubMed  CAS  Google Scholar 

  25. Mulhall JP: Deciphering erectile dysfunction drug trials. J Urol 2003, 170:353–358.

    Article  PubMed  Google Scholar 

  26. von Keitz A, Rajfer J, Segal S, et al.: A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004, 45:499–507. Critical study comparing tadalafil and sildenafil.

    Article  CAS  Google Scholar 

  27. Skoumal R, Chen J, Kula K, et al.: Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004, 46:362–369. Important study.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York University School of Medicine, 150 East 32nd Street, Second Floor, 10016, New York, NY, USA

    Andrew McCullough MD

Authors
  1. Andrew McCullough MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCullough, A. Phosphodiesterase-5 inhibitors: Clinical market and basic science comparative studies. Curr Urol Rep 5, 451–459 (2004). https://doi.org/10.1007/s11934-004-0070-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-004-0070-2

Keywords

Search

Navigation